. Relative intracellular GSH content in XG7 and XG2 myeloma cells. Intracellular GSH level was measured in accordance with Glutathione Assay Kit protocol (ABNOVA). Data are represented as the average +/-SD of an experiment representative of three performed in triplicate.
. Kinetics of melphalan effect on the viability and cell cycle of XG7 and XG2 myeloma cells. A: XG7 cells were treated with 15 µM melphalan (i.e., IC90) and FSC/SSC and cell cycle analyses were performed by flow cytometry after BrdU/DAPI staining before treatment (day 0) and at day 1, 2, 3, 6, 17 after the onset of treatment. B: The percentage of cells in each phase of the cell cycle is indicated. The percentage of viable cells was determined using FSC/SSC characteristics and cell count. C: XG2 cells were treated with 5 µM melphalan (i.e., IC97) and FSC/SSC and cell cycle analysis were performed by flow cytometry after BrdU/DAPI staining before treatment (day 0) and at day 0.5, 3.5, 7, 12, 22 Figure S6 . Addition of 5 mM of GSH protects MM cells from Melphalan induced toxicity. XG2 and XG7 HMCLs were cultured for 1, 2 and 4 days in 96-well flat-bottom microtitre plates in RPMI 1640 medium, 10% fetal calf serum, 2 ng/ml IL-6 culture medium (control) and graded concentration of Melphalan with or without GSH. Data are mean values ± SD of three experiments determined on sextuplet culture wells. * p < 0.05 compared to melphalan alone. Table S1 . XG2 cells were treated with 5 µM melphalan with or without cotreatment with 5 mM GSH. Four days after treatment viability was determined with trypan blue exclusion assay. Cell count and percentage of viable cells for 4 independent experiments are shown in the table.
Treatment
CELL COUNT ± sd VIABILITY % ± sd Untreated 1 685 000 ± 574 739 93 ± 4 GSH 5 mM 1 556 667 ± 592 687 95 ± 2 Melphalan 5 µM 61 208 ± 18 244 18 ± 8 GSH + Melphalan 476 667 ± 148 163 73 ± 13 
